Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.52 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25703950 | 0.81 | NQO2 (0.54) | TNKSFEN1GRM4HPGDKMT2A | |
| SCHEMBL21591678 | 0.80 | FEN1 (0.50) | TNKSFEN1GRM4ELANEHPGD | |
| SCHEMBL5871967 | 0.80 | FEN1 (0.54) | TNKSFEN1GRM4MAPTHPGD | |
| SCHEMBL8692208 | 0.80 | TNKS (0.47) | TNKSFEN1GRM4ELANEMAPT | |
| SCHEMBL8693990 | 0.79 | TNKS (0.49) | TNKSFEN1GRM4MAPTHPGD | |
| SCHEMBL8691823 | 0.79 | TNKS (0.52) | TNKSFEN1MAPTHPGDKMT2A | |
| SCHEMBL21593928 | 0.78 | FEN1 (0.48) | TNKSFEN1GRM4HPGDKMT2A | |
| SCHEMBL13923062 | 0.78 | FEN1 (0.48) | TNKSFEN1GRM4HPGDKMT2A | |
| SCHEMBL830491 | 0.77 | TNKS (0.47) | TNKSFEN1MAPTHPGDKMT2A | |
| SCHEMBL8692400 | 0.77 | TNKS (0.50) | TNKSFEN1MAPTHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421240-B2 | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| CN-113710672-B | Hexahydro-1H-pyrazino [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-114728987-B | 1, 8-Naphthyridin-2-one compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-114599652-B | Hydropyrazino [1,2-d ] [1,4] diazepine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-117597342-A | Pyrrolidine derivative, pharmaceutical composition and application thereof in medicine | 成都百裕制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-3953356-B1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-07-26 | — | — | EP | disclosed |
| EP-3953356-B1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-07-26 | — | — | EP | disclosed |
| US-20230041743-A1 | 1,8-NAPHTHYRIDIN-2-ONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230041743-A1 | 1,8-NAPHTHYRIDIN-2-ONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230034723-A1 | HYDROPYRAZINO[1,2-D][1,4]DIAZEPINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-02-02 | — | — | US | disclosed |
| WO-2020207991-A1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-10-15 | — | — | WO | disclosed |
| US-8143276-B2 | 4-thio substituted quinoline and naphthyridine compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-03-27 | — | — | US | disclosed |
| US-8143276-B2 | 4-thio substituted quinoline and naphthyridine compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-03-27 | — | — | US | disclosed |
| US-8143276-B2 | 4-thio substituted quinoline and naphthyridine compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-03-27 | — | — | US | disclosed |
| EP-2061466-A2 | 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS | Xtl Biopharmaceuticals Ltd. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | PRESIDIO PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | PRESIDIO PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | PRESIDIO PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| WO-2008024423-A2 | 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS | XTL BIOPHARMACEUTICALS LTD. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024423-A2 | 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS | XTL BIOPHARMACEUTICALS LTD. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421240-B2 | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | HRH3, HRH4, HRH2 | TNKS 3008/4885FEN1 4262/4885GRM4 779/4885 |
| US-20230041743-A1 | 1,8-NAPHTHYRIDIN-2-ONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, NFATC1, NAT1 | TNKS 983/4885FEN1 2202/4885GRM4 4529/4885 |
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | GTF3C4, HNF4A, TENT4A | TNKS 511/4885FEN1 2320/4885GRM4 2609/4885 |
| US-20230034723-A1 | HYDROPYRAZINO[1,2-D][1,4]DIAZEPINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HRH3, HRH4, HRH2 | TNKS 3008/4885FEN1 4262/4885GRM4 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.